1. Home
  2. HEPA vs DGLY Comparison

HEPA vs DGLY Comparison

Compare HEPA & DGLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HEPA
  • DGLY
  • Stock Information
  • Founded
  • HEPA 2013
  • DGLY 2004
  • Country
  • HEPA United States
  • DGLY United States
  • Employees
  • HEPA N/A
  • DGLY N/A
  • Industry
  • HEPA Biotechnology: Pharmaceutical Preparations
  • DGLY Radio And Television Broadcasting And Communications Equipment
  • Sector
  • HEPA Health Care
  • DGLY Technology
  • Exchange
  • HEPA Nasdaq
  • DGLY Nasdaq
  • Market Cap
  • HEPA 1.7M
  • DGLY 1.8M
  • IPO Year
  • HEPA N/A
  • DGLY N/A
  • Fundamental
  • Price
  • HEPA $0.17
  • DGLY $0.08
  • Analyst Decision
  • HEPA
  • DGLY
  • Analyst Count
  • HEPA 0
  • DGLY 0
  • Target Price
  • HEPA N/A
  • DGLY N/A
  • AVG Volume (30 Days)
  • HEPA 31.4M
  • DGLY 33.0M
  • Earning Date
  • HEPA 04-15-2025
  • DGLY 04-01-2025
  • Dividend Yield
  • HEPA N/A
  • DGLY N/A
  • EPS Growth
  • HEPA N/A
  • DGLY N/A
  • EPS
  • HEPA N/A
  • DGLY N/A
  • Revenue
  • HEPA N/A
  • DGLY $21,131,122.00
  • Revenue This Year
  • HEPA N/A
  • DGLY $22.14
  • Revenue Next Year
  • HEPA N/A
  • DGLY N/A
  • P/E Ratio
  • HEPA N/A
  • DGLY N/A
  • Revenue Growth
  • HEPA N/A
  • DGLY N/A
  • 52 Week Low
  • HEPA $0.12
  • DGLY $0.07
  • 52 Week High
  • HEPA $3.33
  • DGLY $3.29
  • Technical
  • Relative Strength Index (RSI)
  • HEPA 36.41
  • DGLY 22.91
  • Support Level
  • HEPA $0.17
  • DGLY $0.43
  • Resistance Level
  • HEPA $0.19
  • DGLY $0.11
  • Average True Range (ATR)
  • HEPA 0.02
  • DGLY 0.03
  • MACD
  • HEPA 0.01
  • DGLY 0.00
  • Stochastic Oscillator
  • HEPA 28.55
  • DGLY 6.58

About HEPA Hepion Pharmaceuticals Inc.

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

About DGLY Digital Ally Inc.

Digital Ally Inc produces digital video imaging and storage products for use in law enforcement, security, and commercial applications. Its products are an in-car digital video/audio recorder contained in a rear-view mirror for use in law enforcement and commercial fleets. It can integrate electronic, radio, computer, and multi-media technologies to create solutions to address needs in a variety of other industries and markets, including mass transit, school buses, taxicab, and military. The company sells its products directly to law enforcement agencies, security organizations, and consumer and commercial fleet operators both domestically and internationally through third-party distributors. Its segments include Video Solutions, Revenue Cycle Management, and Entertainment.

Share on Social Networks: